Gastrointestinal Cancers: mCRC (Issue 7) | Special Reports

Neoadjuvant Therapy Continues to Evolve for Pancreatic Cancer

February 25, 2016

Clinical Articles

Neoadjuvant therapy has become increasingly plausible for patients with advanced pancreatic cancer, as the quantity and quality of approved therapies continue to increase, according to Colin Weekes, MD, PhD.

ERCC1 Expression Falls Short as Chemo Biomarker in mCRC

February 18, 2016

Clinical Articles

A potential biomarker to guide the treatment of patients with metastatic colorectal cancer (mCRC) failed to stratify patients by progression-free survival (PFS) or responsiveness to bevacizumab, according to a randomized trial.

Two Options Allows for Treatment Tailoring in Refractory CRC

February 18, 2016

Clinical Articles

Treatments can be better customized and tailored based on each patient's individual desires and characteristics, now that two effective options are available for refractory metastatic colorectal cancer, according to Jennifer Wu, MD.

Dr. Jonathan R. Strosberg on the NETTER-1 Trial and its Impact on Patients With Midgut NETs

February 17, 2016

Clinical Articles

The trial looked at radionuclide therapy Lu-Dotatate in patients with advanced midgut neuroendocrine tumors (NETs), and showed an improvement in overall survival and the reduction of progression or death risk by 79%.

FOLFOXIRI Bests FOLFOX as Bevacizumab Backbone in mCRC

February 17, 2016

Clinical Articles

Marginal improvements were seen in clinical outcomes for patients with metastatic colorectal cancer (CRC) treated with FOLFOXIRI plus bevacizumab compared with FOLFOX plus bevacizumab; however, these findings were inconsistent, according to results from the phase II STEAM trial.